European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups. It ...
Theravance Biopharma’s latest narrative update has nudged its fair value estimate slightly higher to about $26.71 per share, while the discount rate remains effectively unchanged. This modest shift ...
GlaxoSmithKline is set to launch its COPD triple therapy in the US - and must now show that it can maximise sales of the drug with blockbuster potential. Approved yesterday by the FDA, Trelegy Ellipta ...
Medicare beneficiaries will save as much as 85% off the list price when negotiated prices for 15 blockbuster drugs go into effect in 2027, the Centers for Medicare & Medicaid Services (CMS) said ...
Verywell Health on MSN
Comparing asthma inhalers: How to choose
Asthma inhalers can be for quick relief or long-term control. Rescue inhalers work by relaxing your airway muscles to help ...
Trelegy Ellipta is a once-daily, single inhaler triple therapy from GSK, in collaboration with Innoviva, approved as a long-term maintenance treatment for certain patients with chronic obstructive ...
Home Retirement Medicare 15 Costly Drugs Will Get Medicare Price Cuts in 2027: Will You Save? The Centers for Medicare & Medicaid Services extended a safety net to older Americans by announcing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback